Schedule of segment consolidated net loss, including significant segment expenses |
The table below is a summary of the segment net loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | THREE MONTHS ENDED JUNE 30, | | SIX MONTHS ENDED JUNE 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Operating expenses: | | | | | | | | | | | | | Discovery research and development | | $ | 26,244 | | $ | 9,995 | | $ | 48,031 | | $ | 20,392 | Clinical research and development | | | 23,149 | | | 9,304 | | | 40,306 | | | 17,696 | Other research and development expenses | | | 5,317 | | | 2,751 | | | 9,240 | | | 4,641 | General and administrative | | | 15,741 | | | 11,266 | | | 29,185 | | | 22,602 | Total operating expenses | | | 70,451 | | | 33,316 | | | 126,762 | | | 65,331 | Loss from operations | | | (70,451) | | | (33,316) | | | (126,762) | | | (65,331) | Interest and other income, net | | | 8,929 | | | 7,335 | | | 18,505 | | | 13,343 | Loss before provision for income taxes | | | (61,522) | | | (25,981) | | | (108,257) | | | (51,988) | Provision for income taxes | | | 139 | | | 53 | | | 237 | | | 82 | Segment net loss and net loss attributable to ordinary shareholders | | $ | (61,661) | | $ | (26,034) | | $ | (108,494) | | $ | (52,070) | | | | | | | | | | | | | |
|